‹ back to 2026-08-13

Biomarkers of nivolumab benefit in resectable non-small cell lung cancer

Nature Medical/Healthcare AI Tina Cascone, Mark M. Awad, Jonathan D. Spicer, Jie He, Shun Lu, Fumihiro Tanaka, Robin Cornelissen, Lubos B. Petruzelka, Yang Gao, Jean-Louis Pujol, Hiroyuki Ito, Ludmila de Oliveira Muniz Koch, Tudor-Eliade Ciuleanu, Lin Wu, Sabine Bohnet, Yasutaka Watanabe, Janis M. Taube, Julie Stein Deutsch, Cinthya Coronado Erdmann, Stephanie Meadows-Shropshire, Jaclyn Neely, Virginia Ip, Yu-Han Hung, Padma Sathyanarayana, Sumeena Bhatia, Katherine Chu, Steven I. Blum, Stefano Lucherini, Nathanial Eddy, Akshay Yadav, Mariano Provencio 2026-08-12

TL;DR - A Nature study analyzes CheckMate 77T trial participants to identify potential biomarkers predicting benefit from perioperative nivolumab in resectable non-small cell lung cancer. Such biomarkers could help select patients most likely to benefit from immunotherapy.

Uses data from evaluable participants in the CheckMate 77T trial.
Focuses on predictive biomarkers of perioperative nivolumab benefit.
The provided abstract snippet does not specify the biomarkers, methods, or effect sizes.

view merged work →